

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1. **(Currently amended)** A method for inhibiting *in vivo* at least one of the proliferation and growth of lung cancer tissue, which lung cancer tissue expresses *hedgehog*, comprising administering an amount of an agent effective to decrease hedgehog signaling expression in mesenchymal cells surrounding said cancer tissue, wherein said decrease in hedgehog signaling expression in mesenchymal cells alters the proliferation or growth of the lung cancer tissue, and wherein the agent is selected from a *hedgehog* antibody or an *fgf-10* antagonist.
2. **(Currently amended)** A method for inhibiting the growth of a lung tumor, which lung tumor expresses hedgehog, comprising administering an amount of an agent effective to decrease hedgehog signaling expression in mesenchymal cells surrounding said cancer tissue, wherein said decrease in hedgehog signaling expression in mesenchymal cells inhibits the growth of the lung tumor, and wherein the agent is selected from a *hedgehog* antibody or an *fgf-10* antagonist.
3. **(Cancelled)**
4. **(Original)** The method of claim 1, wherein the cell is treated in an animal and the agent is administered to the animal as a therapeutic composition.
5. **(Previously presented)** The method of claim 1 or 2, wherein the agent is a *hedgehog* antibody.
- 6-17. **(Cancelled)**
18. **(Withdrawn)** The method of claim 1, wherein the agent is a *ptc* therapeutic.
19. **(Withdrawn)** The method of claim 18, wherein the *ptc* therapeutic is a small organic molecule which binds to a *patched* protein and derepresses *patched*-mediated inhibition of mitosis.

20. **(Withdrawn)** The method of claims 18, wherein the *ptc* therapeutic binds to *patched* and mimics *hedgehog*-mediated *patched* signal transduction.
21. **(Withdrawn)** The method of claim 20, wherein the *ptc* therapeutic is a small organic molecule.
22. **(Withdrawn)** The method of claim 1 or 2, wherein the *fgf-10* antagonist is a small organic molecule.
23. **(Cancelled)**
24. **(Previously presented)** The method of claim 5, further comprising preparing a formulation including an identified *hedgehog* antibody and a pharmaceutically acceptable excipient.
25. **(Previously presented)** The method of claim 5, wherein the *hedgehog* antibody binds to *hedgehog* and blocks *hedgehog* signal transduction.
26. **(Previously presented)** The method of claim 5, wherein the binding of the *hedgehog* antibody prevents the upregulation of *patched* and/or *gli* expression.
27. **(Previously presented)** The method of claim 5, wherein the *hedgehog* antibody decreases *hedgehog* signal transduction by altering the localization, protein-protein binding and/or enzymatic activity of an intracellular protein involved in a *hedgehog* signal transduction pathway.
28. **(Previously presented)** The method of claim 5, wherein the *hedgehog* antibody alters the level of expression of a *hedgehog* protein, a *patched* protein or a protein involved in a *hedgehog* signal transduction pathway.
- 29-33. **(Cancelled)**

34. **(Withdrawn)** A method for inhibiting at least one of the proliferation and growth of lung cancer cells which express *hedgehog*, comprising contacting the cells with an amount of a *fgf-10* antagonist effective to alter the proliferation or growth of the lung cancer cells, wherein the *hedgehog* antagonist is a small organic molecule.

35. **(Withdrawn)** The method of claim 34, further comprising preparing a formulation including an identified *fgf-10* antagonist and a pharmaceutically acceptable excipient.

36. **(Cancelled)**